Want to see LMRI full AI Analyst Report?

Lumexa Imaging Holdings, Inc. (LMRI) Earnings Dates, Call Summary & Reports

46 Followers

Earnings Data

Report Date

Apr 01, 2027

Before Open (Confirmed)

Period Ending

2026 (Q4)

Consensus EPS Forecast

―

Last Year’s EPS

-0.38

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 5 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:May 12, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed a constructive growth story: revenue and advanced modality volumes expanded (notably PET +23%), adjusted EBITDA held steady at $51.2 million, profitability returned to positive net income, and management reiterated full-year guidance while outlining disciplined growth via de novos, JVs and technology adoption. Near-term headwinds included a roughly $4 million weather and seasonality EBITDA drag, slower routine scans and mammography, higher public company and stock-based compensation costs, and a Q1 free cash flow shortfall. On balance, the operational momentum in high-margin advanced services, improved cash flow trajectory, successful JV and de novo activity, and affirmed guidance outweigh the transitory and timing-related challenges discussed on the call.

Company Guidance

Management reiterated full‑year 2026 guidance of $1.045B–$1.097B in revenue, $234M–$242M of adjusted EBITDA (including roughly $7M of public‑company costs; midpoint adjusted‑EBITDA growth ex those costs ≈7%) and adjusted EPS of $0.71–$0.77, with free cash flow expected to be about 25%–30% of adjusted EBITDA for the year; CapEx is expected to be roughly $5M–$7M per quarter (mid‑to‑upper $20M for the year, with some spend financed via leases). Management expects a gradual sequential ramp in adjusted EBITDA with roughly 55% of full‑year EBITDA in the back half (Q1 ≈21.5% and Q2 ≈23.5% at the midpoint), noted that Q1 results ($253M revenue, adjusted EBITDA $51.2M, 20.3% margin) absorbed an estimated ~$4M hit from seasonality/weather, and highlighted strong advanced modality momentum (system‑wide advanced +7% YoY; PET +23.1% YoY; MRI +8.2% YoY), a FastScan MRI adoption target of ~66–67% by year‑end (from 51% at start of year) and the ongoing plan to open 8–10 de novos annually.

Revenue Growth and Scale

Consolidated revenues of $253 million, up 3% year-over-year, and system-wide revenue growth of 4% for the quarter, driven approximately two-thirds by volume and one-third by rate.

Strong Advanced Modality Performance

Advanced modalities grew 7% year-over-year system-wide and consolidated, with PET up 23.1% year-over-year and MRI up 8.2% year-over-year; advanced scans comprised 37.4% of total volume, a 160 basis point improvement versus Q1 2025.

Profitability Improvement and EPS

Pretax income improved to $3 million from a pretax loss of $4 million in Q1 2025; net income was $2 million versus a net loss of $8 million prior year. GAAP EPS was $0.02 and adjusted EPS was $0.18.

Adjusted EBITDA Resilience

Adjusted EBITDA was $51.2 million, essentially flat versus $51.1 million a year ago, with an adjusted EBITDA margin of 20.3% and management reiterating full-year adjusted EBITDA guidance of $234 million to $242 million.

Improved Cash Flow Profile

Cash flows from operating activities were $3 million, a $17 million improvement year-over-year, and free cash flow was negative $2 million, a $13 million improvement versus prior year; interest expense run rate fell by about $14 million versus Q1 2025 after IPO debt paydown.

Disciplined Capital Deployment and Guidance

Q1 CapEx of $5 million with expected quarterly CapEx of $5 million to $7 million (mid-to-upper $20s full year). Full-year revenue guidance of $1.045 billion to $1.097 billion and adjusted EPS guidance of $0.71 to $0.77 reaffirmed.

Growth via De Novos, JVs and M&A

Opened 4 new centers (2 tuck-in acquisitions and 2 de novos) in Q1, completed first IDTF acquisition in Pennsylvania as part of the UPMC JV, and have 15 centers opened since late 2024 that are ramping; company targeting 8 to 10 de novos annually.

Technology and Operational Enhancements

FastScan deployment driving MRI productivity; beginning the year at 51% MRI fleet adoption and targeting roughly 66-67% by year-end. Virtual cockpit remote MRI scanning and AI-enabled offerings (breast arterial calcification) expanding strategic service lines and efficiency.

Lumexa Imaging Holdings, Inc. (LMRI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LMRI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 01, 2027	2026 (Q4)	- / -	-0.38	―	―	―
May 12, 2026	2026 (Q1)	0.12 / 0.19	-0.081	330.86% (+0.27)	―
Mar 26, 2026	2025 (Q4)	0.05 / -0.38	-0.265	-43.40% (-0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LMRI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 12, 2026	$10.50	$8.05	-23.33%
Mar 26, 2026	$11.06	$7.76	-29.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lumexa Imaging Holdings, Inc. (LMRI) report earnings?

Lumexa Imaging Holdings, Inc. (LMRI) is schdueled to report earning on Apr 01, 2027, Before Open (Confirmed).

What is Lumexa Imaging Holdings, Inc. (LMRI) earnings time?

Lumexa Imaging Holdings, Inc. (LMRI) earnings time is at Apr 01, 2027, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LMRI EPS forecast?

Currently, no data Available